Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases

Ori Elkayam, Jacob Ablin, Dan Caspi

Research output: Contribution to journalReview articlepeer-review

Abstract

Vaccination against streptococcus pneumonia is currently recommended for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Safety and efficacy issues of vaccination in patients suffering from rheumatic diseases are still unresolved. This review summarizes the studies performed on the safety and immunogenicity of pneumococcal vaccination in patients with RA and SLE, with special emphasis on the effect of immunosuppressive drugs on the efficacy of the vaccine. Several trials have shown that the vaccine does not induce clinical exacerbation of RA and that it does induce an adequate humoral response, albeit one lower than that in healthy controls.

Original languageEnglish
Pages (from-to)312-314
Number of pages3
JournalAutoimmunity Reviews
Volume6
Issue number5
DOIs
StatePublished - Apr 2007
Externally publishedYes

Keywords

  • Pneumovax
  • RA
  • SLE
  • Vaccination

Fingerprint

Dive into the research topics of 'Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases'. Together they form a unique fingerprint.

Cite this